NAV

Girentuximab

Identification

Generic Name
Girentuximab
DrugBank Accession Number
DB05304
Background

Girentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Chimeric (human-murine) G250 IgG monoclonal antibody
  • Girentuximab
External IDs
  • CA9-SCAN CG250
  • cG 250
  • cG250
  • WX G250
  • WX-G 250
  • WX-G250

Pharmacology

Indication

Investigated for use/treatment in gall bladder cancer and renal cell carcinoma.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Mechanism of action of girentuximab is antibody dependent cellular cytotoxicity (ADCC). As a monotherapy in metastatic renal cell carcinomas(RCC), girentuximab demonstrated minimal clinical activity with a 3% partial response rate and a median survival of 16 months. In vitro data suggest that the number of activated ADCC effector cells can be upregulated by low dose interleukin 2 (IL2) administered in a pulsatile fashion.

TargetActionsOrganism
UCarbonic anhydrase 9Not AvailableHumans
UInterleukin-2Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Girentuximab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Girentuximab.
AducanumabThe risk or severity of adverse effects can be increased when Girentuximab is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Girentuximab.
AlirocumabThe risk or severity of adverse effects can be increased when Girentuximab is combined with Alirocumab.
AmivantamabThe risk or severity of adverse effects can be increased when Girentuximab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Girentuximab is combined with Anifrolumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Girentuximab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Girentuximab is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Girentuximab is combined with Antilymphocyte immunoglobulin (horse).
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Rencarex

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
539B57DFJF
CAS number
916138-87-9

References

General References
  1. Carney WP: Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Expert Rev Mol Diagn. 2007 May;7(3):309-19. [Article]
PubChem Substance
347910066
Wikipedia
Girentuximab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentRenal Cancer1
3WithdrawnDiagnosticRenal Cancer / Renal Cell Carcinoma (RCC)1
2CompletedTreatmentMetastatic Clear Cell Renal Cell Carcinoma (ccRCC)1
2Not Yet RecruitingDiagnosticCervical Cancer / Cholangiocarcinoma / Colorectal Cancer / Epithelial Ovarian Cancer / Esophageal Cancer / Gastric Cancer / Glioblastoma Multiforme (GBM) / Hepatocellular Carcinoma / Nasopharyngeal Carcinoma (NPC) / Non-Small Cell Lung Cancer (NSCLC) / Pancreatic Ductal Adenocarcinoma (PDAC) / Small Cell Lung Cancer (SCLC) / Soft Tissue Sarcoma / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Not Yet RecruitingTreatmentAdvanced Malignant Neoplasm / Clear Cell Renal Cell Carcinoma1
2RecruitingTreatmentAdvanced Renal Cell Carcinoma / Clear Cell Renal Cell Carcinoma / Renal Cancer1
2, 3CompletedDiagnosticRenal Cell Carcinoma (RCC)1
1CompletedTreatmentRenal Cancer / Renal Cell Carcinoma (RCC) / Renal Neoplasms1
1RecruitingDiagnosticRenal Cell Carcinoma (RCC)1
1RecruitingDiagnosticUrothelial Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Carbonic anhydrase 9
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Participates in pH regulation. May be involved in the control of cell proliferation and transformation. Appears to be a novel specific biomarker for a cervic...
Gene Name
CA9
Uniprot ID
Q16790
Uniprot Name
Carbonic anhydrase 9
Molecular Weight
49697.36 Da
Details2. Interleukin-2
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Kinase activator activity
Specific Function
Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimu...
Gene Name
IL2
Uniprot ID
P60568
Uniprot Name
Interleukin-2
Molecular Weight
17627.52 Da

Drug created at November 18, 2007 18:23 / Updated at December 01, 2022 23:18